LB Pharmaceuticals Inc announced a Private Placement on February 4, 2026, to issue 3,306,571 shares at $21.17 each and warrants to purchase an additional 1,417,107 shares, aiming to raise approximately $100 million for a Phase 2 trial of LB-102 for major depressive disorder and working capital.